Objective:To understand the efficacy of gene hepatitis B vaccine associated with hepatitis B immune globulin on interrupting the mather-infant transmission of HBV and to explore the most effective immunotherapy plan.Methods:A total of 99 cases of HBsAg-positive pregnant women were chosen as investigation objects

which were then divided into test and control groups by various testing period.According to the different vaccination ways of hepatitis B vaccine

test groups were divided into Group A(muscular injection way)and Group B(intradermal injection way).Pregnant women in the test groups were intramuscularly injected with HBIG of 200IU at week 28

32 and 36 of gestation;the neonates were intramuscularly injected with HBIG of 200IU at postnatal 4 h

and on the 15th and 30th day and vaccinated gene Hepatitis B vaccine of 5 μg at birth date

a month and six months after birth respectively.Control group were routinely inoculated by hepatitis B vaccine.HBsAg and anti-HBs in the serum were monitored by following-up the children for five years.Results:The blocking rate of mother-infant transmission of HBV in test group was 98.36%

however

the blocking rate of control group was 83.33%(P<0.05)

but there was no significant difference between group A and group B(P>0.05).The blocking rate in HBeAg and HBsAg-positive group was 77.78%

but

in HBsAg-positive group

the blocking rate was 97.26%(P<0.05).The HBs-positive rate in the first year had no significant difference between test group and control group

but significant differences appeared in the fifth year.Conclusion:HBIG associated with hepatitis B vaccination could significantly improve blocking rate of mater-infant vertical transmission of HBV.For HBsAg positive pregnant women

the blocking rate of HBV was higher than that of HBeAg and HBsAg positive pregnant women.